{"id":874710,"date":"2026-08-31T06:32:09","date_gmt":"2026-08-31T06:32:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/874710\/"},"modified":"2026-08-31T06:32:09","modified_gmt":"2026-08-31T06:32:09","slug":"bell-potter-says-this-asx-healthcare-share-could-rise-200","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/874710\/","title":{"rendered":"Bell Potter says this ASX healthcare share could rise 200%+"},"content":{"rendered":"

Saluda Medical Inc (ASX: SLD<\/a>) shares had a day to forget on Friday.<\/p>\n

The ASX healthcare share ended the week with a 25% decline to 48 cents after the market responded negatively to its FY 2026 results.<\/p>\n

While this is disappointing, the team at Bell Potter believes it could have created a very attractive buying opportunity.<\/p>\n

\"Happy<\/p>\n

Image source: Getty Images<\/p>\n

What is the broker saying?<\/p>\n

Saluda Medical is a medical device company commercialising spinal cord stimulation (SCS) therapy.\u00a0<\/p>\n

Bell Potter notes the ASX healthcare share reported higher than expected operating expenses in FY 2026, which resulted in a sizeable adjusted EBITDA<\/a> loss. It said:<\/p>\n

Revenue was pre-released at the Q4 update, increasing +28% for the full year with a particularly strong 2H (up +38% on pcp). Gross margin of 48.9% was ahead of our forecast (48.5%) and improved +2.3% yoy. Opex was above our forecast, resulting in loss at EBITDA (adjusted) of -$113.7m albeit still coming better than Prospectus guidance of -$114.7m.<\/p>\n

However, there were positives. It adds:<\/p>\n

In SLD’s first full-year result since listing, management has beaten each key metric guided to at the time of the IPO (revenue, EBITDA loss, cashflow<\/a>). Closing cash balance was $116m and excludes $25m of undrawn debt available under the Perceptive loan available to be drawn down in 1H FY27.<\/p>\n

Looking ahead, Bell Potter points out that management is guiding to more strong top line growth and another EBITDA loss. It adds:<\/p>\n

The company provided four key FY27 guidance statements: (1) revenue growth of 25-35% ($113m-122m); (2) gross margin 50%-52% while reiterating the longer-term target of ‘mid-60s’ once the next generation IPG and percutaneous leads are submitted to and approved by the FDA (launch guided to CY27); (3) adjusted EBITDA loss $101-95m; and (4) revenue growth to outpace opex growth.\u00a0<\/p>\n

Big potential returns<\/p>\n

Bell Potter remains very positive on the ASX healthcare share.<\/p>\n

In response to its results, the broker has retained its buy rating and $1.60 price target on its shares.<\/p>\n

Based on its current share price, this implies potential upside of approximately 230% for investors over the next 12 months.<\/p>\n

Speaking about its buy thesis, Bell Potter said:<\/p>\n

SLD’s US commercial execution continues to impress and accelerated considerably in recent quarters (34% US growth in Q3, 45% in Q4). Tailwinds continue to build following FDA approval of SLD’s paddle lead in June and ~40% of the current sales force expected to complete training in FY27 and contribute to revenue generation. Real-world data continues to affirm Evoke’s value proposition: greater efficacy durability means fewer reprogramming requirements and therefore greater revenue\/rep compared to conventional devices.<\/p>\n","protected":false},"excerpt":{"rendered":"Saluda Medical Inc (ASX: SLD) shares had a day to forget on Friday. The ASX healthcare share ended…\n","protected":false},"author":2,"featured_media":874711,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-874710","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/874710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=874710"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/874710\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/874711"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=874710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=874710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=874710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}